[en] Pituitary adenomas occur in a familial setting in multiple endocrine neoplasia type 1 (MEN1) and Carney's complex (CNC), which occur due to mutations in the genes MEN1 and PRKAR1A respectively. Isolated familial somatotropinoma (IFS) is also a well-described clinical syndrome retated only to patients with acrogigantism. Pituitary adenomas of all types - not limited to IFS - can occur in a familial setting in the absence of MEN1 and CNC; this phenotype is tcrmed familial isolated pituitary adenomas (FIPA). Over the past 7 years, we have described over 90 FIPA kindreds. In FIPA, both homogeneous and heterogeneous pituitary adenoma phenotypes can occur within families; virtually all FIPA kindreds contain at least one prolactinoma or somatotropinoma. FIPA differs from MEN1 in terms of a lower proportion of prolactinomas and more frequent somatotropinomas in the FIPA cohort. Patients with FIPA are significantly younger at diagnosis and have significantly larger pituitary adenomas than matched sporadic pituitary adenoma counterparts. A minority of FIPA families overall (15%) exhibit mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene; AIP mutations are present in only half of IFS kindreds occurring as part of the FIPA cohort. In families with AIP mutations, pituitary adenomas have a penetrance of over 50%. AIP mutations are extremely rare in patients with sporadic pituitary adenomas. This review deals with pituitary adenomas that occur in a familial setting, describes in detail the clinical, pathological, and genetic features of FIPA, and addresses aspects of the clinical approach to FIPA families with and without AIP mutations.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Beckers, Albert ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Daly, Adrian ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Language :
English
Title :
The clinical, pathological, and genetic features of familial isolated pituitary adenomas
Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML & McCutcheon IE. The prevalence of pituitary adenomas: a systematic review. Cancer 2004 101 613-619.
Davis JR, Farrell WE & Clayton RN. Pituitary tumours. Reproduction 2001 121 363-371.
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA & Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. Journal of Clinical Endocrinology and Metabolism 2006 91 4769-4775.
Asa SL & Ezzat S. Genetics and proteomics of pituitary tumors. Endocrine 2005 28 43-47.
Scheithauer BW, Laws ER Jr, Kovacs K, Horvath E, Randall RV & Carney JA. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Seminars in Diagnostic Pathology 1987 4 205-211.
Agarwal SK, Lee Burns A, Sukhodolets KE, Kennedy PA, Obungu VH, Hickman AB, Mullendore ME, Whitten I, Skarulis MC, Simonds WF, Mateo C, Crabtree JS, Scacheri PC, Ji Y, Novotny EA, Garrett-Beal L, Ward JM, Libutti SK, Richard Alexander H, Cerrato A, Parisi MJ, Santa Anna-A S, Oliver B, Chandrasekharappa SC, Collins FS, Spiegel AM & Marx SJ. Molecular pathology of the MEN1 gene. Annals of the New York Academy of Sciences 2004 1014 189-198.
Vergès B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C & Calender A. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. Journal of Clinical Endocrinology and Metabolism 2002 87 457-465.
Daly AF, Jaffrain-Rea ML & Beckers A. Clinical and genetic features of familial pituitary adenomas. Hormone and Metabolic Research 2005 37 347-354.
Wautot V, Vercherat C, Lespinasse J, Chambe B, Lenoir GM, Zhang CX, Porchet N, Cordier M, Beroud C & Calender A. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Human Mutation 2002 20 35-47.
Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, Fend F, Graw J & Atkinson MJ. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. PNAS 2006 103 15558-15563.
Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, Vierimaa O, Mäkinen MJ, Tuppurainen K, Paschke R, Gimm O, Koch CA, Gündogdu S, Lucassen A, Tischkowitz M, Izatt L, Aylwin S, Bano G, Hodgson S, De Menis E, Launonen V, Vahteristo P & Aaltonen LA. Germline CDKN1B/p27kip1 mutation in multiple endocrine neoplasia. Journal of Clinical Endocrinology and Metabolism 2007 (Epub).
Ozawa A, Agarwal SK, Mateo CM, Burns AL, Rice TS, Kennedy PA, Quigley CM, Simonds WF, Weinstein LS, Chandrasekharappa SC, Collins FS, Spiegel AM & Marx SJ. The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. Journal of Clinical Endocrinology and Metabolism 2007 92 1948-1951.
Carney JA, Hruska LS, Beauchamp GD & Gordon H. Dominant inheritance of the complex of myxomas, spotty pigmentation and endocrine overactivity. Mayo Clinic Proceedings 1985 61 165-172.
Stergiopoulos SG & Stratakis CA. Human tumors associated with Carney complex and germline PPKAR1A mutations: a protein kinase A disease! FEBS Letters 2003 546 59-64.
Veugelers M, Wilkes D, Burton K, McDermott DA, Song Y, Goldstein MM, La Perle K, Vaughan CJ, O'Hagan A, Bennett KR, Meyer BJ, Legius E, Karttunen M, Norio R, Kaariainen H, Lavyne M, Neau JP, Richter G, Kirali K, Farnsworth A, Stapleton K, Morelli P, Takanashi Y, Bamforth JS, Eitelberger F, Noszian I, Manfroi W, Powers J, Mochizuki Y, Imai T, Ko GT, Driscoll DA, Goldmuntz E, Edelberg JM, Collins A, Eccles D, Irvine AD, McKnight GS & Basson CT. Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. PNAS 2004 101 14222-14227.
Boikos SA & Stratakis CA. Pituitary pathology in patients with Carney Complex: growth-hormone producing hyperplasia or tumors and their association with other abnormalities. Pituitary 2006 9 203-209.
Pack SD, Kirschner LS, Pak E, Zhuang Z, Carney JA & Stratakis CA. Genetic and histological studies of somatomammotropic tumors in patients with the 'Complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas' (Carney complex). Journal of Clinical Endocrinology and Metabolism 2000 85 3860-3865.
Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T, Ferolla P, Emy P, Colao A, De Menis E, Lecomte P, Penfornis F, Delemer B, Bertherat J, Wemeau JL, De Herder W, Archambeaud F, Stevenaert A, Calender A, Murat A, Cavagnini F & Beckers A. Clinical characterization of familial isolated pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2006 91 3316-3323.
Verloes A, Stevenaert A, Teh BT, Petrossians P & Beckers A. Familial acromegaly: case report and review of the literature. Pituitary 1999 1 273-277.
Frohman LA & Eguchi K. Familial acromegaly. Growth Hormone and IGF Research 2004 14 S90-S96.
Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, Gundogdu S, De Menis E, Makinen MJ, Launonen V, Karhu A & Aaltonen LA. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006 312 1228-1230.
Teh BT, Kytölä S, Farnebo F, Bergman L, Wong FK, Weber G, Hayward N, Larsson C, Skogseid B, Beckers A, Phelan C, Edwards M, Epstein M, Alford F, Hurley D, Grimmond S, Silins G, Walters M, Stewart C, Cardinal J, Khodaei S, Parente F, Tranebjaerg L, Jorde R, Menon J, Khir A, Tan TT, Chan SP, Zaini A, Khalid BAK, Sandelin K, Thompson N, Brandi ML, Warth M, Stock J, Leisti J, Cameron D, Shepherd JJ, Öberg K, Nordenskjöld M & Salmela P. Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 1998 83 2621-2626.
Poncin J, Abs R, Velkeniers B, Bonduelle M, Abramowicz M, Legros JJ, Verloes A, Meurisse M, Van Gaal L, Verellen C, Koulischer L & Beckers A. Mutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type 1 and related diseases. Human Mutation 1999 13 54-60.
Luccio-Camelo DC, Une KN, Ferreira RE, Khoo SK, Nickolov R, Bronstein MD, Vaisman M, Teh BT, Frohman LA, Mendonca BB & Gadelha MR. A meiotic recombination in a new isolated familial somatotropinoma kindred. European Journal of Endocrinology 2004 150 643-648.
Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G, Raverot G, Barlier A, De Herder W, Penfornis A, Ciccarelli E, Estour B, Lecomte P, Gatta B, Chabre O, Sabate MI, Bertagna X, Garcia Basavilbaso N, Stalldecker G, Colao A, Ferolla P, Wemeau JL, Caron P, Sadoul JL, Oneto A, Archambeaud F, Calender A, Sinilnikova O, Montanana CF, Cavagnini F, Hana V, Solano A, Delettieres D, Luccio-Camelo DC, Basso A, Rohmer V, Brue T, Bours V, Teh BT & Beckers A. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. Journal of Clinical Endocrinology and Metabolism 2007 92 1891-1896.
Linquette M, Herlant M, Laine E, Fossati P & Dupont-Lecompte J. Adenome a prolactine chez une jeune fine dont la mere etait porteuse d'un adenome hypophysaire avec amenorrhee-galactorrhee. Annales d'Endocrinologie 1997 28 773-780.
Berezin M & Karasik A. Familial prolactinoma. Clinical Endocrinology 1995 42 483-486.
Salti IS & Mufarrij IS. Familial Cushing disease. American Journal of Medical Genetics 1981 8 91-94.
Yuasa H, Tokito S, Nakagaki H & Kitamura K. Familial pituitary adenoma - report of four cases from two unrelated families. Neurologia Medico-Chirurgica 1990 30 1016-1019.
Valdes-Socin H, Poncin J, Stevens V, Stevenaert A & Beckers A. Adenomes hypophysaires familiaux isoles non lies avec la mutation somatique NEM-1. Suivi de 27 patients. Annales d'Endocrinologie 2000 61 301.
Valdes-Scoin H, Jaffrain Rea ML, Tamburrano G, Cavagnini F, Cicarelli E, Colao A, Delemer B, Brue T, Rohmer V, Wemeau JL, Levasseur S, The B, Stevenaert A & Beckers A. Familial isolated pituitary tumors: clinical and molecular studies in 80 patients. Endocrine Society's 84th Annual Meeting 2002 P3-663 647.
Beckers A. Familial isolated pituitary adenomas. The Ninth International Workshop on multiple endocrine neoplasia (MEN2004). Journal of Internal Medicine 2004 255 696-730.
Ciccarelli A, Daly AF & Beckers A. The epidemiology of prolactinomas. Pituitary 2005 8 3-6.
Petrossians P, de Herder W, Kwekkeboom D, Lamberigts G, Stevenaert A & Beckers A. Malignant prolactinoma discovered by D2 receptor imaging. Journal of Clinical Endocrinology and Metabolism 1999 85 398-401.
Ackermann F, Krohn K, Windgassen M, Buchfelder M, Fahlbusch R & Paschke R. Acromegaly in a family without a mutation in the menin gene. Experimental and Clinical Endocrinology and Diabetes 1999 107 93-96.
Jorge BH, Agarwal SK, Lando VS, Salvatori R, Barbero RR, Abelin N, Levine MA, Marx SJ & Toledo SP. Study of the multiple endocrine neoplasia type 1, growth hormone-releasing hormone receptor, Gs alpha, and Gi2 alpha genes in isolated familial acromegaly. Journal of Clinical Endocrinology and Metabolism 2001 86 542-544.
Khoo SK, Chan S, Pendek R, Jayaram M, Kanthimanti MS, Wong FK, Motorna O, Valdes-Socin H, Frohman L, Jaffrain-Réa ML, Tamburrano G, Beckers A & Teh B. Clinical and genome-wide linkage studies of a multigenerational family with acromegaly and the exclusion of requiem gene. Endocrine Society's 84th Annual Meeting 2002 Pl-680 312.
Yu R, Bonert S, Saporta I, Raffel LJ & Melmed S. AIP variants in sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2006 91 5126-5129.
Barlier A, Vanbellinghen JF, Daly AF, Silvy M, Jaffrain-Rea ML, Trouillas J, Tamagno G, Cazabat L, Bours V, Brue T, Enjalbert A & Beckers A. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2007 92 1952-1955.
Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T & Yoshimoto K. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clinical Endocrinology 2007 66 499-502.
Toledo RA, Lourenco DM Jr, Liberman B, Cunha-Neto MB, Cavalcanti MG, Moyses CB, Toledo SP & Dahia PL. Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. Journal of Clinical Endocrinology and Metabolism 2007 92 1934-1937.
Carver LA, LaPres JJ, Jain S, Dunham EE & Bradfield CA. Characterization of the Ah receptor-associated protein, ARA9. Journal of Biochemical Chemistry 1999 273 33580-33587.
Petrulis JR & Perdew GH. The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chemico-Biological Interactions 2002 141 25-40.
Meyer BK, Petrulis JR & Perdew CH. Aryl hydrocarbon (Ah) receptor levels are selectively modulated by hsp90-associated immunophilin homolog XAP2. Cell Stress and Chaperones 2000 5 243-254.
Bell DR & Poland A. Binding of aryl hydrocarbon receptor (AhR) to AhR-interacting protein. The role of hsp90. Journal of Biological Chemistry 2000 275 36407-36414.
Meyer BK & Perdew GH. Characterization of the AhR-hsp90-XAP2 core complex and the role of the immunophilin-related protein XAP2 in AhR stabilization. Biochemistry 1999 38 8907-8917.
Georgitsi M, Raitila A, Karhu A, Tuppurainen K, Makinen MJ, Vierimaa O, Paschke R, Saeger W, van der Luijt RB, Sane T, Robledo M, De Menis E, Weil RJ, Wasik A, Zielinski G, Lucewicz O, Lubinski J, Launonen V, Vahteristo P & Aaltonen LA. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. PNAS 2007 104 4101-4105.
Georgitsi M, Karhu A, Winqvist R, Visakorpi T, Waltering K, Vahteristo P, Launonen V & Aaltonen LA. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. British Journal of Cancer 2007 96 352-356.
Lees MJ, Peet DI & Whitelaw ML. Defining the role for XAP2 in stabilization of the dioxin receptor. Journal of Biological Chemistry 2003 278 35878-35888.
Lee K, Burgoon LD, Lamb L, Dere E, Zacharewski TR, Hogenesch JB & Lapres JJ. Identification and characterization of genes susceptible to transcriptional cross-talk between the hypoxia and dioxin signaling cascades. Chemical Research in Toxicology 2006 19 1284-1293.
Harper PA, Riddick DS & Okey AB. Regulating the regulator: factors that control levels and activity of the aryl hydrocarbon receptor. Biochemical Pharmacology 2006 72 267-279.
Ohtake F, Takeyama K, Matsumoto T, Kitagawa H, Yamamoto Y, Nohara K, Tohyama C, Krust A, Mimura J, Chambon P, Yanagisawa J, Fujii-Kuriyama Y & Kato S. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 2003 423 545-550.
Bolger GB, Peden AH, Steele MR, MacKenzie C, McEwan DG, Wallace DA, Huston E, Baillie GS & Houslay MD. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. Journal of Biological Chemistry 2003 278 33351-33363.
de Oliveira SK, Hoffmeister M, Gambaryan S, Muller-Esterl W, Guimaraes JA & Smolenski AP. Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. Journal of Biological Chemistry 2007 282 13656-13663.
Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW,
Tomassetti P, Tonelli F, Wells SA Jr & Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 2001 86 5658-5671.
Wassif WS, Moniz CF, Friedman E, Wong S, Weber G, Nordenskjold M, Peters TJ & Larsson C. Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. Journal of Clinical Endocrinology and Metabolism 1993 77 1485-1489.
Carrasco CA, Gonzalez AA, Carvajal CA, Campusano C, Oestreicher E, Arteaga E, Wohllk N & Fardella CF. Novel intronic mutation of MEN1 gene causing familial isolated primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2004 89 4124-4129.
Warner J, Epstein M, Sweet A, Singh D, Burgess J, Stranks S, Hill P, Perry-Keene D, Learoyd D, Robinson B, Birdsey P, Mackenzie E, Teh BT, Prins JB & Cardinal J. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. Journal of Medical Genetics 2004 41 155-160.
Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD & Marx SJ. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. Journal of Clinical Endocrinology and Metabolism 2004 89 96-102.
Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B & Dralle H. European Multiple Endocrine Neoplasia (EUROMEN) Study Group. Early malignant progression of hereditary medullary thyroid cancer. New England Journal of Medicine 2003 349 1517-1525.
Gimm O, Greco A, Hoang-Vu C, Dralle H, Pierotti MA & Eng C. Mutation analysis reveals novel sequence variants in NTRK1 in sporadic human medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1999 84 2784-2787.
Naves LA, Daly AF, Vanbellinghen J-F, Casulari LA, Spilioti C, Magalhâes AV, Azevedo MF, Giacomini LA, Nascimento PP, Mines RO, Rosa JWC, Jaffrain-Rea M-L, Bours V & Beckers A. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. European Journal of Endocrinology 2007 157 383-391.
Ramadoss P, Petrulis JR, Hollingshead ED, Kusnadi A & Perdew GH. Divergent roles of hepatitis B virus X-associated protein 2 (XAP2) in human versus mouse Ah receptor complexes. Biochemistry 2004 43 700-709.
Gueorguiev M, Quinton R, Chapple R, Leontiou C, Lolli F, Wass JA, Popovic V, Ribeiro-Oliveira A, Gadelha MR, Clayton RN, Jordan S, Frohman LA, Grossman AB & Korbonits M. The role of AIP in familial acromegaly. Endocrine Society's 89th Annual Meeting 2007 OR15-2.
Sakurai A, Katai M, Hashizume K & Fukushima Y. Familial neuroendocrine tumor syndromes: from genetics to clinical practice. Pituitary 2006 9 231-236.
Melmed S. Aryl hydrocarbon receptor interacting protein and pituitary tumorigenesis: another interesting protein. Journal of Clinical Endocrinology and Metabolism 2007 92 1617-1619.
Besser GM, Burman P & Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. European Journal of Endocrinology 2005 153 187-193.
Cazabat L, Libe R, Perlemoine K, Rene-Corail F, Burnichon N, Gimenez-Roqueplo AP, Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P, Bertherat J & Raffin-Sanson ML. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. European Journal of Endocrinology 2007 157 1-8.
